Publications

Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Nosocomial- and Community-Acquired Infections in United States Hospitals (2014-2016), Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1215

Activity of Delafloxacin When Tested against Bacterial Surveillance Isolates Collected in the US and Europe during 2014-2016 as Part of a Global Surveillance Program, Lead author: Flamm RK, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1222

Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers (2013-2016), Lead Author: Sader HS, presented at IDWeek 2017, October 4-7, San Diego, CA, USA
Poster #1232

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2012-2016) Enterobacteriaceae and Pseudomonas aeruginosa Isolates by US Census Division, Lead author: Shortridge D, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1216

Evaluation of In Vitro Activity of Ceftaroline Tested against Streptococcus pneumoniae Isolates from United States Hospitals: Results from 7 Years of the AWARE Surveillance Program (2010-2016), Lead author: Pfaller MA, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1239

Activity of Plazomicin against Enterobacteriaceae Isolates Collected in the United States Including Isolates Carrying Aminoglycoside-Modifying Enzymes Detected by Whole Genome Sequencing, Lead author: Castanheira, M, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1235

Ceftobiprole Activity When Tested against Contemporary Bacteria Causing Bloodstream Infections in the US (2016), Lead author: Flamm RK, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1205

Yearly Trends of Antimicrobial Nonsusceptibility among Streptococcus pneumoniae Serotypes Causing Infection in Adult Patients in the United States (2009-2015), Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1496

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Enterobacteriaceae and Pseudomonas aeruginosa from United States Medical Centers Stratified by Infection Type (2015-2016), Lead author: Sader HS, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1237

In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary Community-Acquired Bacterial Respiratory Tract Infection Isolates (2014-2106): Results from the SENTRY Antimicrobial Surveillance Program, Lead author: Shortridge D, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1208

Analysis of Oritavancin Activity Against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008-2016), Lead author: Pfaller MA, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1207

Antimicrobial Activity of Dalbavancin and Comparator Agents Tested against Gram-Positive Clinical Isolates Causing Bone and Joint Infections in United States Medical Centers (2011-2016), Lead Author: Sader HS, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1221

Distributions and Annual Changes of Streptococcus pneumoniae Serotypes Causing Infections in Adult Patients: 8 Years of US Surveillance (2009-2016), Lead author: Arends SJR, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1500

Cefepime-Zidebactam (WCK 5222) Activity Tested against Gram-Negative Organisms Causing Bloodstream Infections Worldwide, Lead author: Sader HS, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1226

Activity of Meropenem-Vaborbactam (VABOMERE^TM) against Enterobacteriaceae Isolates carrying bla_kpc Collected Worldwide, Lead author: Castanheira, M, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1234

In Vitro Activity of Omadacycline and Comparator Compounds against Gram-Positive Isolates Collected in the US During 2016 as Part of a Global Surveillance Program, Lead author: Huband MD, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1223

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2012-2016) Enterobacteriaceae and Pseudomonas aeruginosa from ICU vs Non-ICU Respiratory Isolates Collected in US Medical Centers, Lead author: Shortridge D, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1198

Broad In Vitro Activity Analysis of Tedizolid Compared with Other Agents against a Global Collection of Gram-Positive Isolates Causing Bloodstream Infections (2014-2016), Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1210

Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Pediatric Patients in the US during 2012-2016 as Part of a Global Surveillance Program, Lead author: Shortridge D, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1202

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Tested against Contemporary (2016) Clinical Enterobacteriaceae Isolates, Lead author: Sader HS, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1233

Antimicrobial Activity of Dalbavancin Tested against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from United States Medical Centers, Lead author: Sader HS, presented at IDWeek 2017, October 4-7, San Diego, CA, USA
Poster #1238

Molecular Characterization of Fluoroquinolone Resistance Mechanisms in Gram-Negative Isolates from the Delafloxacin Acute Bacterial Skin and Skin Structure Infections Clinical Trials, Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #331

Sustained In Vitro Activity of Linezolid and Evolving Resistance Mechanisms: Summary of the Zyvox^® Annual Appraisal of Potency and Spectrum Program for 2016, Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #329

Characterization of β-Lactam Resistance Mechanisms among Baseline Pseudomonas aeruginosa from 5 Ceftazidime-Avibactam Phase 3 Clinical Trials, Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #326

Regional Analysis of Resistance Phenotypes among Staphylococcus aureus Causing Infections in US Census Divisions: Telavancin Activity against Resistant Pathogens (2014-2016), Lead author: Duncan LR, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #333

Characterization of Enterobacter and Citrobacter spp. Isolates from United States Hospitals by Whole Genome Sequencing Analysis and Activity of Ceftazidime-Avibactam and Comparator Agents, Lead author: Castanheira M, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #320

Antimicrobial resistance among Gram-positive bacteria isolated in Latin American hospitals. by Sader HS, Moet GJ, Jones RN published in J Chemother 2009; 21 (6): 611-620

Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. by Sader HS, Fey PD, Fish DN, Limaye AP, Pankey G, Rahal J, Rybak MJ, Snydman DR, Steed LL, Waites K and Jones RN published in Antimicrob. Agents Chemother. 2009; 53 (10): 4127-4132

Resurgence of Pseudomonas endocarditis in Detroit, 2006-2008. by Reyes MP, Ali A, Mendes RE and Biedenbach DJ published in Medicine (Baltimore) 2009; 88 (5): 294-301

Strategic design of an effective β-lactamase inhibitor: LN-1-255, a 6-alkylidene-2′-substituted penicillin sulfone. by Pattanaik P, Bethel CR, Hujer AM, Hujer KM, Distler AM, Taracila M, Anderson VE, Fritsche TR, Jones RN, Pagadala SR, van den Akker F, Buynak JD and Bonomo RA published in J. Biol. Chem. 2009; 284 (2): 945-953

Antipseudomonal activity of piperacillin/tazobactam: More than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007). by Jones RN, Stilwell MG, Rhomberg PR and Sader HS published in Diagn. Microbiol. Infect. Dis. 2009; 65(3): 331-334

Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone resistance-determining regions. by Hirakata Y, Ohmori K, Mikuriya M, Saika T, Matsuzaki K, Hasegawa M, Hatta M, Yamamoto N, Kunishima H, Yano H, Kitagawa M, Arai K, Kawakami K, Kobayashi I, Jones RN, Kohno S, Yamaguchi K and Kaku M published in Antimicrob. Agents Chemother. 2009; 53 (10): 4225-4230

Antimicrobial susceptibility of Gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005-2008). by Gales AC, Sader HS, Ribeiro J, Zoccoli C, Barth A and Pignatari AC published in Braz J Infect Dis 2009; 13 (2): 90-98

Comparison of 2002-2006 OPTAMA programs for US hospitals: Focus on gram-negative resistance. by Crandon JL, Kuti JL, Jones RN and Nicolau DP published in Ann. Pharmacother. 2009; 43 (2): 220-227.

Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections. by Fritsche TR, Rhomberg PR, Sader HS and Jones RN. published in Antimicrob. Agents Chemother. 2008; 52 (3): 1187-1189

Treatment of severe infections in the era of high rates of antimicrobial resistance. by Sader HS and Gales AC published in Braz. J. Infect. Dis. 2008; 12 (Suppl 2): S1-S2

Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. by Lodise TP, Nau R, Kinzig M, Drusano GL, Jones RN and Sorgel F, published in J Antimicrob Chemother 2007; 60 (5): 1038-1044

CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program. by Pfaller MA, Messer SA, Rhomberg PR and Castanheira M published in Int. J. Antimicrob. Agents 2017; 50 (3): 352-358

Determination of disk diffusion and MIC quality control guidelines for high dose cefepime-tazobactam (WCK 4282), a novel antibacterial combination consisting of a beta-lactamase inhibitor and a fourth-generation cephalosporin. by Riedel S, Huband MD, Sader HS, Flamm RK and Jones RN published in J. Clin. Microbiol. 2017; 55 (10): 3130-3134.

Monitoring antifungal resistance in a global collection of invasive yeasts and moulds: Application of CLSI epidemiological cutoff values and whole genome sequencing analysis for detection of azole resistance in Candida albicans. by Castanheira M, Deshpande LM, Davis AP, Rhomberg PR and Pfaller MA published in Antimicrob. Agents Chemother., 2017; 61 (10): e00906

ZAAPS Program results for 2015: An activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries. by Pfaller MA, Mendes RE, Streit JM, Hogan PA and Flamm RK published in J. Antimicrob. Chemother., 2017;72 (11): 3093-3099

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an antimicrobial surveillance program (2013-2015). by Pfaller MA, Shortridge D, Sader HS, Flamm RK and Castaneheira M published in J. Glob. Antimicrob. Resist. 2017: 10; 186-194

Telavancin activity in vitro tested against a worldwide collection of gram-positive clinical isolates (2014). by Duncan LR, Sader HS, Smart JI, Flamm RK and Mendes RE published in J. Glob. Antimicrob. Resist.2017; 10: 271-276

Activity of dalbavancin tested against gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014 – 2015). by Pfaller MA, Mendes RE, Sader HS, Castanheira M and Flamm RK published in J. Glob. Antimicrob. Resist. 2017; 11: 4-7

In vitro activity of telavancin against clinically important gram-positive pathogens from 69 U.S. medical centers (2015): Potency analysis by U.S. census divisions. by Pfaller MA, Sader HS, Flamm RK, Castanheira M, Smart JI and Mendes RE published in Microb. Drug Resist., 2017; 23 (6): 718-726

Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from US hospitals: Report from an antimicrobial surveillance program (PACTS, 2012-2015). by Shortridge D, Castanheira M, Pfaller MA and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61: e00465

Antimicrobial susceptibility trends among Staphylococcus aureus from United States hospitals: Results from 7 years of the ceftaroline (AWARE) surveillance program (2010-2016). by Sader HS, Mendes RE, Streit JM and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (9): e01043

Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and Echinocandin-resistant strains of Candida spp. by Pfaller MA, Messer SA, Rhomberg PR and Castanheira M published in Antimicrob. Agents Chemother. 2017; 61 (8): e00161

In vitro activity of linezolid against clinically important gram-positive cocci in the United States: A 5-year summary of in vitro activity and resistance mechanisms from the LEADER Surveillance Program (2011-2015). by Pfaller MA, Mendes RE, Streit JM, Hogan PA and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (7): e00609

Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV. by Mitton-Fry MJ, Brickner SJ, Hamel JC, Barham R, Brennan L, Casavant JM, Ding X, Finegan S, Hardink J, Hoang T, Huband MD, Maloney M, Marfat A, McCurdy SP, McLeod D, Subramanyam C, Plotkin M, Reilly U, Schafer J, Stone GG, Uccello DP, Wisialowski T, Yoon K, Zaniewski R and Zook C published in Bioorg. Med. Chem. Lett. 2017; 27 (15): 3353-3358